Около

The balance of evidence suggests that men with T2DM, metabolic syndrome and HG are likely to benefit from testosterone therapy combined with lifestyle intervention. There appeared to be slight increased risk of CV events in the first 6 months that could have been related to increased risk caused by low testosterone before patients reached therapeutic targets. Crucially, data on fatal CV events and all-cause mortality data was not collected, despite testosterone therapy in other studies having a major impact on mortality rather than event numbers. However, there were concerns regarding the exclusion of 1,132 patients who experienced events because they were prescribed testosterone therapy after the event, when they should have been included in the untreated group, increasing the events by 70%. Of the 1,223 patients receiving testosterone therapy, 67 died, 23 suffered MIs and 33 experienced strokes. During a mean follow-up of 840 days, 681 of the 7,486 patients not receiving testosterone therapy died, 420 suffered MIs and 486 experienced strokes.
At the end of the study, total testosterone increased in both groups with neither group deriving more benefit than the other (p ≥ 0.244). A meta-analysis of RCTs developed in support of this guideline indicate that there is no significant difference in MACE in men on testosterone therapy when compared to placebo. The risk corresponded to an additional 10 cases per 10,000 person-years, which, while low in absolute terms, raised concern about using testosterone therapy in men who may be at increased risk for VTE prior to commencement of therapy.362 Available studies are retrospective in nature but have suggested that post-RT patients (with or without ADT exposure) placed on testosterone therapy do not experience recurrence of prostate cancer. While the lack of a baseline semen analysis before commencement of the initial exogenous testosterone therapy is a possible weakness of this study, the methodology mirrors the clinical scenario for a large percentage of men starting exogenous testosterone with no prior semen testing.For men already on exogenous testosterone who are planning future reproduction, testosterone cessation should occur in advance of initiation of any effort to conceive. Overall, seven studies reported no benefits on QoL in men using testosterone therapy compared to placebo,199, 205, 212, 225, 226, 230, 303, 318 while five studies demonstrated improvements.203, 317, 319, 328, 329
In this way, diabetes, obesity, and low testosterone are closely connected, creating a cycle that can be difficult to break. This conversion process can reduce the overall amount of testosterone in the body, contributing to low T in men who are overweight or obese. As a result, men with insulin resistance may produce less testosterone than those without it. This relationship is largely due to how diabetes affects the body’s hormone regulation and metabolism. Research shows that about one-third of men with type 2 diabetes also have low testosterone. For men, testosterone is responsible for regulating sex drive, maintaining muscle mass, and helping with the production of red blood cells. The answer is yes—having diabetes can increase the likelihood of developing low testosterone, especially in men.
A second important factor that contributed to the more widespread use of testosterone was the development of more patient-friendly formulations. While increasing awareness of and demand for a medication may be beneficial if the risk-benefit ratio of the drug is favorable, that assumption is questionable for many men taking testosterone for nonspecific symptoms without a clear diagnosis. We concluded that the relationship between testosterone and insulin resistance in men is bidirectional. These symptoms can overlap with those of poorly controlled diabetes, making diagnosis challenging. Regular check-ups, proper diagnosis, and effective treatment can improve outcomes for those living with both conditions. Both conditions can negatively impact a person’s health, but with proper management, the risks can be minimized.
Other limitations included the possible subjective nature in reporting some adverse events.Conversely, the Shores, 367 Muraleedharan,233 and Baillargeon373 studies determined that there was no increased risk of MACE in men who were on testosterone therapy. Two of the retrospective studies included in the FDA review pointed to an increased risk of cardiovascular events in men on testosterone therapy. Mean peak total testosterone levels are dose-dependent, with a mean of 746, 866, and 913 ng/dL noted with 8, 10, and 12 pellets administered (not BMI adjusted).446 The duration of effect is similar, however, and is relatively independent of dosing. Men with total testosterone level 315 ng/dL declined from 100% at 4 weeks to 86%, 75%, and 14% by 12, 20, and 24 weeks, respectively.Mean peak total testosterone levels are dose-dependent, with a mean of 746, 866, and 913 ng/dL noted with 8, 10, and 12 pellets administered (not BMI adjusted).446 The duration of effect is similar, however, and is relatively independent of dosing. Administration of 750 mg of IM testosterone undecanoate at weeks 0, 4, and every 10 weeks thereafter maintained total testosterone levels between 300-1,000 ng/dL for 94% of men.438 No men experienced maximal values Adverse Effects.
The strengths of this study are the longitudinal design, the standardized cut off used to define HG, and the confirmation of biochemical hypogonadism, as well as the evaluation of clinical symptoms using a standardized questionnaire. In contrast, the population enrolled in our study had a mean HbA1c of 7.2% (SD +/− 1.8). Conversely, our study showed no significant deterioration of any CGM parameters. To date, this evaluation is not yet estimated; anyway, there are many studies that are prsovided to evaluate the role of glycometabolic parameters in these populations, giving the basis to explore the effect of TRT on glycemic variability to literature. This pilot study assessed the impact of TRT on glycemic variability in men affected by DM and hypogonadism. None of the subjects developed erythrocytosis, as well as alteration in blood count, or had pathological PSA increase (Table 2).
For diabetic men, this can be confusing because diabetes itself can affect sexual function. Muscle loss can also make it harder to manage blood sugar because muscles use glucose for energy. If a diabetic man feels unusually tired even when his blood sugar is controlled, low T could be the reason.
The present pilot study is a proof of concept with the aim to evaluate the short-term effect of TRT on glycemic variability, assessed by CGM, in subjects with T2DM. Anyway, no studies are available that are evaluating the direct effects of TRT on glycemic variability. In particular, there is a lack of data about the effect of TRT on glycemic variability, which has acquired increased importance as a marker of glycemic control . Hypogonadism also affect up to 35–40% of male subjects with DM, mainly type 2 (T2) DM 4,5,6; the heterogeneity of the results depend on cut offs used to define hypogonadism and the study design . Diabetes mellitus (DM) is a major global health problem, with DM-related complications being a main cause of increased morbidity and mortality.